Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2000
|
| gptkbp:ATCCode |
N03AF02
|
| gptkbp:availableOn |
gptkb:tablet
oral suspension |
| gptkbp:CASNumber |
28721-07-5
|
| gptkbp:chemicalFormula |
C15H12N2O2
|
| gptkbp:contraindication |
hypersensitivity to oxcarbazepine
|
| gptkbp:discoveredBy |
gptkb:Ciba-Geigy
|
| gptkbp:drugClass |
anticonvulsant
|
| gptkbp:eliminationHalfLife |
1-5 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:genericName |
gptkb:oxcarbazepine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Trileptal
|
| gptkbp:interactsWith |
gptkb:phenytoin
gptkb:valproic_acid gptkb:carbamazepine phenobarbital oral contraceptives |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
voltage-gated sodium channel blocker
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness drowsiness hyponatremia |
| gptkbp:usedFor |
epilepsy
partial seizures |
| gptkbp:bfsParent |
gptkb:NOVN
|
| gptkbp:bfsLayer |
5
|